Literature DB >> 16375696

Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics.

N J Sarlis1, L Gourgiotis.   

Abstract

Cytochrome P450 (CYP) is a group of enzymes that metabolize drugs to a more water-soluble form, rendering them available for renal excretion. The major site of CYP expression is the liver. Nearly 50% of all medications currently on the market are metabolized by the enzyme CYP3A4, while metabolism of another 35-40% occurs through enzymes CYP1A2, CYP2C19, CYP2D6, CYP3A5 CYP3A6, and CYP3A7. Here, we summarize the current knowledge of the effects of hormones on the CYP family. The term "hormone" is used in its broad sense and includes products of the major endocrine glands (i.e., thyroid, adrenals, gonads, pancreas) and compounds that are not classically considered hormones, such as neurogenic amines, cytokines, interleukins, and eicosanoids. In addition, we comment on the effects on CYP expression of states associated with profound hormonal changes, such as pregnancy, malnutrition, obesity, diabetes mellitus, systemic inflammation, and conditions of altered extracellular fluid volume or osmolality. Available data are limited and are derived primarily from in vitro and animal studies. Moreover, the picture is obscured by conflicting results among studies and the complexity of the regulation of the expression and activity of elements of the CYP system. While the clinical significance of hormonal effects on the CYP system remains to be determined, we anticipate that such effects will be most pertinent to drugs with a narrow therapeutic range. Further research is needed to determine the scope and significance of these effects in view of rapid advances in the field of pharmacogenomics and the ever-increasing number of drugs available for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375696     DOI: 10.2174/156800805774912971

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  9 in total

1.  Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Tomohiro Hayashi; Mai Fujimoto; Kouichi Hosomi; Akira Oita; Mitsutaka Takada
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

2.  Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.

Authors:  Pier Luigi Calvo; Loredana Serpe; Andrea Brunati; Antonello Nonnato; Daniela Bongioanni; Dominic Dell' Olio; Michele Pinon; Carlo Ferretti; Francesco Tandoi; Giulia Carbonaro; Mauro Salizzoni; Antonio Amoroso; Renato Romagnoli; Roberto Canaparo
Journal:  Br J Clin Pharmacol       Date:  2017-01-31       Impact factor: 4.335

3.  Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio: could a drug-induced toxicity be regulating exposure to the offending agent?

Authors:  Andrew Rowland; Angela Rowland; Michael J Sorich; Arduino A Mangoni
Journal:  Eur J Clin Pharmacol       Date:  2017-05-03       Impact factor: 2.953

4.  CYP2E1 activity and children with obesity: possible confounding factors.

Authors:  Hardeep Kaur; Phulen Sarma; Ajay Prakash; Bikash Medhi
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

5.  Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.

Authors:  Katrijn Bogman; Mariabeth Silkey; Siew Pheng Chan; Brian Tomlinson; Cornelia Weber
Journal:  Eur J Clin Pharmacol       Date:  2010-06-12       Impact factor: 2.953

6.  Response: Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio; could a drug-induced toxicity be regulating exposure to the offending agent?

Authors:  Mitsutaka Takada; Mikie Yamato; Kyoichi Wada; Mai Fujimoto; Kouichi Hosomi; Tomohiro Hayashi; Akira Oita
Journal:  Eur J Clin Pharmacol       Date:  2017-04-30       Impact factor: 2.953

7.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

8.  Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy.

Authors:  Kwi Hye Koh; Steve Jurkovic; Kyunghee Yang; Su-Young Choi; Jin Woo Jung; Kwang Pyo Kim; Wei Zhang; Hyunyoung Jeong
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

9.  Development of the first marmoset-specific DNA microarray (EUMAMA): a new genetic tool for large-scale expression profiling in a non-human primate.

Authors:  Nicole A Datson; Maarten C Morsink; Srebrena Atanasova; Victor W Armstrong; Hans Zischler; Christina Schlumbohm; Bas E Dutilh; Martijn A Huynen; Brigitte Waegele; Andreas Ruepp; E Ronald de Kloet; Eberhard Fuchs
Journal:  BMC Genomics       Date:  2007-06-25       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.